Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
AssigneeVicept Therapeutics, Inc.
InventorsStuart D. Shanler, Andrew Ondo
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α1-adrenergic receptor (α1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
Claims24
A method for treating at least one condition selected from the group consisting of rosacea, acne, skin redness or other conditions characterized by discreet erythema of the skin in a subject in need of such treatment, comprising administering topically to said subject, for such period of time as is required to elicit the desired therapeutic response, a therapeutically or cosmetically effective amount of at least one alpha-1 adrenoreceptor agonist.
A composition for topical administration to the skin for treating rosacea comprising oxymetazoline HCl and an inert carrier.
An acne and rosacea treatment composition comprises:
- an effective amount of an acne and rosacea treatment composition to treat acne, which composition includes:
- (a) An acne treatment medication selected from the group consisting of benzoyl peroxide and salicylic acid;
- (b) A vasoconstrictor selected from the group consisting of an alpha one adrenoreceptor agonist, and
- (c) An inert carrier,
- wherein, when said benzoyl peroxide is the acne treatment medication, it is in an amount of about 0.1% to about 20% based on the total weight of the composition, and when said salicylic acid is the acne treatment medication, it is in an amount of 0.05% to 15.0% based on the total weight of the composition;
- and, wherein said vasoconstrictor is in an amount of about 0.05% to about 20% by weight, based on the total weight of the composition.
Dependencies are inferred from the claim text.